Amgen and Entera Bio call off oral drug delivery partnership after four years
Amgen and Entera Bio are calling off a four-year research collaboration “out of mutual convenience,” Entera revealed in its first-quarter results.
The Jerusalem-based biotech is developing new ways to administer macromolecules orally, which is expected to allow patients to skip injections. When Amgen put down $725,000 in early 2019 for access to the company’s oral drug delivery platform, the drugmaker planned to use the platform in an undisclosed preclinical large molecule program, with the promise of paying Entera up to $270 million in milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.